文献速递药物相互作用特殊人群用药

齐泊腾坦与含炔雌醇/左炔诺孕酮避孕药可安全联用:药代动力学药物相互作用研究

Zibotentan Can Be Co-administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug-Drug Interaction Study.
PubMed 文献 · Clin Pharmacol Ther · 2024-04-30

本研究在24名无生育能力的健康女性中开展单序列自身对照研究,比较单用炔雌醇/左炔诺孕酮与联用齐泊腾坦(10 mg 每日一次)时的药代动力学。结果显示齐泊腾坦不影响炔雌醇暴露,对左炔诺孕酮暴露有弱相互作用(AUCinf几何均值比1.30),但无临床相关性,提示含炔雌醇/左炔诺孕酮的避孕药可在齐泊腾坦治疗期间使用。

要点

  • 齐泊腾坦10 mg每日一次不影响炔雌醇的药代动力学。
  • 左炔诺孕酮暴露轻度增加(AUCinf比值1.30),被视为无临床相关性。
  • 含炔雌醇/左炔诺孕酮的避孕药可在齐泊腾坦治疗期间使用。

核心结论

  • 齐泊腾坦与含炔雌醇/左炔诺孕酮的避孕药联用未导致避孕药暴露降低,左炔诺孕酮的弱暴露增加无临床相关性,故认为可联用。

研究设计与样本

  • 单序列、参与者内比较研究,纳入24名无生育能力的健康女性。
  • 第1天和第15天单次口服炔雌醇0.06 mg/左炔诺孕酮0.3 mg;第6-19天每日一次口服齐泊腾坦10 mg。
  • 比较第1天与第15天炔雌醇/左炔诺孕酮的药代动力学参数(Cmax、AUCinf)的几何最小二乘均值比。

主要发现

  • 齐泊腾坦联用后炔雌醇Cmax几何均值比1.05(90%CI 0.99-1.11),AUCinf几何均值比1.00(90%CI 0.96-1.05)。
  • 齐泊腾坦联用后左炔诺孕酮Cmax几何均值比1.12(90%CI 1.02-1.23),AUCinf几何均值比1.30(90%CI 1.21-1.39)。
  • 多剂量齐泊腾坦未降低炔雌醇/左炔诺孕酮的血浆暴露。

临床怎么用

  • 对于接受齐泊腾坦治疗的育龄女性,可选择含炔雌醇/左炔诺孕酮的避孕药进行高效避孕。

局限性

  • 研究人群为无生育能力的健康女性,可能不完全代表育龄女性。
  • 研究为单序列自身对照设计,未设安慰剂或平行对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The endothelin A receptor antagonist zibotentan, combined with the sodium-glucose co-transporter-2 inhibitor dapagliflozin, is being investigated for the treatment of chronic kidney disease with high proteinuria. To allow women of childbearing potential access to this treatment, highly effective contraception is required and drug interactions compromising contraception reliability must be avoided. This study investigated the risk of pharmacokinetic (PK) interaction between zibotentan and the contraceptives ethinyl estradiol and levonorgestrel. A single-sequence, within-participant comparison study was conducted in 24 healthy women of non-childbearing potential, comparing the PK of ethinyl estradiol/levonorgestrel alone and with zibotentan. Single oral doses of 0.06 mg ethinyl estradiol/0.3 mg levonorgestrel were administered on Days 1 and 15; zibotentan 10 mg was dosed orally, once-daily through Days 6-19. PK profiles were determined and ethinyl estradiol/levonorgestrel PK was compared between Day 1 and 15 based on geometric least-squares mean ratios of PK parameters, including maximum observed concentration (Cmax) and area under the plasma concentration-time curve from zero to infinity (AUCinf). Co-administration with zibotentan did not affect ethinyl estradiol PK (geometric mean ratio [90% confidence interval] Cmax 1.05 [0.99-1.11], AUCinf 1.00 [0.96-1.05]), while a weak interaction (increased exposure) was observed for levonorgestrel (Cmax 1.12 [1.02-1.23], AUCinf 1.30 [1.21-1.39]), which was regarded as without clinical relevance. Plasma exposure of ethinyl estradiol/levonorgestrel was not reduced by multiple-dose zibotentan. In conclusion, contraception containing ethinyl estradiol/levonorgestrel is regarded possible under zibotentan-containing treatments. This expands choices for women of childbearing potential, supporting diversity in the ZENITH High Proteinuria trial.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mercier AK, Kois AK, Karsanji D, et al. Zibotentan Can Be Co-administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug-Drug Interaction Study. Clin Pharmacol Ther. 2024. PMID: 38686600. doi:10.1002/cpt.3280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。